Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON31299
NL-OMON31299
Recruiting
Not Applicable

Influence of B cell depletion therapy (rituximab) on (risk factors of) comorbidity in rheumatoid arthritis - B cell depletion therapy in rheumatoid arthritis and comorbidity

Vrije Universiteit Medisch Centrum0 sites50 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsrheumatoid arthritis100822061000381610023213

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
rheumatoid arthritis
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
50
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •According to the thesis of the Dutch association of rheumatology (NVR): treatment with rituximab of rheumatoid arthritis patients:
  • •\- rheumatoid arthritis diagnosed according to the ACR criteria 1987
  • •\- active rheumatoid arthritis
  • •\- previous failure of TNF alpha blocking

Exclusion Criteria

  • •\- malignity
  • •\- active tuberculosis or other active infection
  • •\- pregnancy and lactation
  • •\- severe heart failure (NYHA IV) or other cardiac disease
  • •\- hypersensitivity to one of the active substances of rituximab or murine proteins

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Study on the efficacy of rituximab in patients with polymyalgia rheumaticapolymyalgia rheumatica
NL-OMON27507one. This is an investigator initiated trial50
Active, not recruiting
Not Applicable
Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren diseasePreviously treated patients with primary Sjögrens diseaseMedDRA version: 8.0Level: PTClassification code 10040767
EUCTR2005-004740-31-DKniversity of Copenhagen34
Completed
Phase 2
Effect of B-cell Depletion in Patients With Primary Sjögren's SyndromePrimary Sjögren's SyndromeXerostomiaHyposalivationKeratoconjunctivitis SiccaFatigue
NCT00426543University of Copenhagen21
Completed
Not Applicable
Effect of three B-cell inhibitors: rituximab, alemtuzumab and bortezomib on anti-A and/or anti-B titer kinetics.kidneytransplant1001884910038430
NL-OMON39959eids Universitair Medisch Centrum24
Not yet recruiting
Phase 2
Comparing Use of B-cell depletion therapy to Immunoglobulin in Chronic inflammatory demyelinating polyneuropathy (CUBIC) clinical trial.Chronic inflammatory demyelinating polyneuropathy (CIDP).Inflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disorders
ACTRN12623001336673Western Sydney Local Health District35